News and Trends 31 Mar 2023 Sofinnova Partners dives into digital medicine, funds new companies Sofinnova Partners, a European life sciences venture capital firm based in Paris, London, and Milan, has launched a new investment strategy focused on digital medicine. The strategy, which has already seen Sofinnova Partners investing in biotech companies, will be headed by partners Edward Kliphuis and Simon Turner. Sofinnova Digital Medicine will back entrepreneurs innovating at […] March 31, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 21 Jul 2022 Finding investment opportunities in a bleak biotech stock market The situation remains difficult in public markets as biotech stocks struggle to recover from a 50% decline over the past year. However, the venture capital (VC) firm Sofinnova Partners is no stranger to downturns, and partner Joe Anderson explains how the industry is shifting in favor of life sciences investors. It’s a tough time to […] July 21, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 May 2022 US Giant Apollo Bags Billion-Euro Partnership with Sofinnova As biotech investment slows following a record-breaking year, the Paris-based Sofinnova Partners has landed a €1B collaboration deal with the US investment heavyweight Apollo to nurture life sciences companies. Cementing the trend for transatlantic deals between biotech investors, the US asset manager Apollo has entered into a billion-Euro partnership with the European venture capitalist (VC) […] May 17, 2022 - 3 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
Opinion 14 Mar 2022 The Secrets to 50 Years of Success in Life Sciences Investment The European life sciences venture capital firm Sofinnova Partners is celebrating its 50th birthday this year. Sofinnova’s Chairman and Managing Partner, Antoine Papiernik, outlines key lessons the company has learned in its long history in the biotech industry. Meet a couple who have been married for 50 years and most of us, I imagine, would […] March 14, 2022 - 7 minutesmins - By Antoine Papiernik Share WhatsApp Twitter Linkedin Email
News and Trends 10 Dec 2021 European Biotech Investors Cap Off Record Year in Fundraising The year 2021 is closing with a biotech investment rush as Eir Ventures, Apollo Health Ventures, and Merck’s venture capital arm M Ventures raise impressive funds to speed up life sciences innovation. This year is set to break records in terms of the money flowing into institutional life science investors. With 2021 not even finished, […] December 10, 2021 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2021 Sustainability in Focus as Two VCs Build Industrial Biotech Funds As this month’s COP26 United Nations climate summit highlighted the climate change emergency, venture capital fundraises from Sofinnova and the European Circular Bioeconomy Fund have led the push for industrial biotechnology to further shift the global economy away from fossil fuels. Yesterday, the venture capital (VC) firm Sofinnova Partners raised €150M for an early-stage environmental […] November 18, 2021 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2021 Biotech VCs Face Funding Bulge Amid Struggling Stock Markets Despite volatile biotech stocks limiting options for exit, Sofinnova Partners’ latest €472M fund highlights ballooning European venture capital and its growing focus on early-stage biotech investments. Biotech fundraising broke records in 2020 as the Covid-19 pandemic swept the globe. This year seems set to continue biotech’s winning streak in private fundraising. One example is a […] October 19, 2021 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jul 2021 Multi-Million UK Life Sciences Initiative Welcomed By VC Firms Biotech venture capital firms across Europe have warmly received the launch of a €235M (£200M) UK government initiative to support the growth of promising late-stage life sciences companies. The UK’s Life Sciences Investment Programme opened to applications from fund managers this month, with the aim of providing €235M in late-stage capital and attracting at least […] July 16, 2021 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2021 Sofinnova Taps into Italian Gene Therapy with Three Seed Financings The French investor Sofinnova Partners has injected a total of €6M into three Italian gene therapy companies, cementing Italy’s reputation as a European center for cell and gene therapies. Last month, the venture capitalist Sofinnova Partners used its Telethon fund to inject cash into AAVantgarde Bio, Borea Therapeutics, and Alia Therapeutics. The three firms will […] July 12, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
Opinion 8 Mar 2021 Advice for my Younger Self: How to Be a VC in Life Sciences Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners, looks back at where he was two decades ago and shares what he would tell his younger self about being a life sciences VC. I am not a scientist or a doctor. Twenty years ago, when I was starting my career in this business, someone like […] March 8, 2021 - 5 minutesmins - By Antoine Papiernik Share WhatsApp Twitter Linkedin Email
News and Trends 4 Dec 2020 EU Launches Pharma Strategy, Raising Both Hopes and Questions The public’s response has been cautious after the European Union unveiled a pharmaceutical strategy last week designed to spur domestic innovation and the production of affordable, state-of-the-art therapies. Amid a boom in biotech funding driven by the Covid-19 pandemic, the European Commission (EC) is scrambling to bring its sometimes fragmented pharma regulatory framework up to […] December 4, 2020 - 6 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 1 Oct 2020 Medicxi to Shake up the Biotech VC Investment Model with €200M Fund UK-based investment firm Medicxi aims to attract more investors to the life sciences with a new fund that lets them cash in on their investments earlier than conventional funds. Last week, Medicxi closed a €200M fund called Medicxi Secondary 1 (MS1), which was co-led by the UK’s Pantheon and Switzerland’s LGT Capital Partners. The aim […] October 1, 2020 - 4 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email